• Bio Products Laboratory Support for Strong Trade Links with India
  May 04, 2021
• BPL and Atlantic Research Group enter into long-term collaboration
  April 28, 2021
• Bio Products Laboratory: £23m Investment in New 1,000 Square Meter Filling and Sterilisation Facility at Elstree
  March 29, 2021
• BPL Sells 25 US Plasma Centres to Grifols for $370 million
  March 01, 2021
• Bio Products Laboratory Receives Triangle Business Journal’s Fast 50 Award
  October 19, 2020
• BPL Announces October 10th Hereditary Factor X Deficiency Awareness Day
  October 08, 2020
• Bio Products Laboratory USA Recognized as Triangle Business Journal’s Best Places to Work
  September 14, 2020
• Fourth update on BPL’s continued efforts during the COVID-19 pandemic
  June 05, 2020
• Bio Products Laboratory Announces Launch of ALBUMINEX^® 5% and ALBUMINEX^® 25% With Supply Immediately Available in the United States
  May 27, 2020
• Third update on BPL’s work to ensure the provision of critical medicines in response to the COVID-19 pandemic
  May 06, 2020
• Further Update on BPL’s actions to ensure the provision of critical medicines in response to the worldwide COVID-19 pandemic
  April 07, 2020
• Global plasma leaders collaborate to accelerate development of potential Covid-19 hyperimmune therapy
  April 06, 2020
• COVID-19 and Update on Actions Taken to Ensure Patient Needs Will Continue to be Met
  March 18, 2020
• FDA Approves Bio Products Laboratory’s Gammaplex® 10% for Treatment of Primary immunodeficiency and Chronic Immune Thrombocytopenic Purpura
  February 07, 2017
• Bio Products Laboratory Receives European Approval for Coagadex® (Human Coagulation Factor X)
  March 30, 2016
• Bio Products Laboratory Announces Supply of COAGADEX® Now Available in the United States
  December 03, 2015
• Press Release: Bio Products Laboratory Receives FDA approval for Coagadex® (Coagulation Factor X, Human) First-ever FDA-approved treatment for hereditary factor X deficiency
  October 21, 2015
• Press Release: Gammaplex® Approved For Use In Pediatric Patients
  October 21, 2015
• Press Release: FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)
  May 27, 2015
• Press Release: Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product
  April 17, 2015
• Bio Products Laboratory Inc. (BPL) announces NEW vial size of Gammaplex® for the treatment of Primary Immunodeficiency and Chronic Immune Thrombocytopenic Purpura
  June 16, 2014
• Press Release: Change of name to BPL Holdings for Plasma Resources UK
  January 01, 2014
• Press Release: BPL announces strong progress on the world’s first licensed Factor X product
  December 31, 2013
• Press Release: Change of Ownership
  September 01, 2013
• Parliamentary Year Book
  January 28, 2013
• Press Release on Investment Request
  September 01, 2012
• Approval Letter - Gammaplex
  September 17, 2009